Monitor ASCO 2026 oral presentation on May 29 for additional detail and any safety signals; watch for initiation of the registrational Phase 2 and potential regulatory discussions. The stock's recent negative drift suggests this may already be partially discounted.
REGN drugs
REGN drug pipeline →- ● Otarmeni 3/10 Approved (accelerated approval) · BLA filing 2026
- ▲ Cemdisiran 6/10 Filed/PDUFA (Phase 3 NIMBLE complete; NDA under FDA Priority Review)
- ▲ Dupixent 4/10 Approved (marketed since 2017; additional Phase 3 trials ongoing for label expansion)
- ● Evkeeza 4/10 Approved
- ● EYLEA HD 4/10 Approved
- 12 more · All REGN drugs, catalysts & trials →
How the stock moved after the report
BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · May 22 $638.53entry
- T+1 · 6mo ago −1.00%α −1.58% · $632.17
- T+5 · 6mo ago −5.93%α −7.59% · $600.65
- T+20 · 5mo ago −4.08%α −3.91% · $612.50
- T+60 · 3mo ago +26.47%α +23.55% · $807.57
Price Chart
How similar events traded
Executive Summary
Regeneron announced positive Phase 1/2 LINKER-AL2 results for Lynozyfic (linvoseltamab) in second-line-plus systemic AL amyloidosis, with 100% hematologic complete response at the highest tested dose (240 mg) and rapid normalization of free light chains by day 15. The drug is already approved for multiple myeloma, and the Phase 2 portion with registrational intent is ongoing, but no approved therapies currently exist for this indication after initial treatment failure, making this an early-stage, high-potential but uncertain pipeline catalyst.
Key Facts
- 100% (13/13) hematologic complete response at 240 mg dose in Phase 1/2 LINKER-AL2 trial for second-line-plus systemic AL amyloidosis
- Rapid normalization of involved free light chains by day 15 across all doses
- 73% (8/11) renal and 50% (4/8) cardiac organ improvement observed
- Phase 2 portion with registrational intent is ongoing; currently no approved therapies post-initial treatment for AL amyloidosis
- Lynozyfic already approved for relapsed/refractory multiple myeloma under a different generic name (linvoseltamab-gcpt)
- Median follow-up of 9.5 months; responses durable with no hematologic progression in patients still in trial
Financial Impact
No revenue figures disclosed; potential TAM of ~4,400 U.S. cases/year for AL amyloidosis, with Lynozyfic already approved for MM. Data readout could expand label, but commercialization timeline uncertain.
Risk Factors
- Small sample size (n=20) and short follow-up; results may not persist in larger registrational trial
- SAEs included one fatal ventricular fibrillation (assessed unrelated) and one sudden death in cardiac amyloidosis context
- No approved therapies exist for this indication, but regulatory path uncertain and competitive landscape may evolve
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3299793 |
Track record
53 reports on REGN
11 of 16 bullish or bearish reports moved the stock their way by T+20. Best: +31.76% at T+20 after the Oct 6, 2026 report. 16 of 20 went positive at some point.
Filters
- Nov 16, 2026today 144 Neutral 2/10 Entry $951.23 Now $952.40 +0.12% settles Dec 16
- Nov 16, 2026today 144 Neutral 2/10 Entry $948.00 Now $952.40 +0.46% settles Dec 16
- Nov 12, 20264d ago Press Release Bullish 5/10 Entry $955.47 Now $952.40 −0.32% settles Dec 14
- Nov 5, 202611d ago Insider Cluster Neutral 2/10 Entry $904.35 Now $952.40 +5.31% settles Dec 7
- Nov 5, 202611d ago Insider Cluster Neutral 3/10 Entry $904.35 Now $952.40 +5.31% settles Dec 7
- Nov 4, 202612d ago 144 Neutral 1/10 Entry $902.90 Now $952.40 +5.48% settles Dec 4
- Nov 4, 202612d ago 144 Neutral 2/10 Entry $902.90 Now $952.40 +5.48% settles Dec 4
- Nov 3, 202613d ago Insider Cluster Neutral 2/10 Entry $930.67 Now $952.40 +2.33% settles Dec 3
- Nov 3, 202613d ago 144 Neutral 2/10 Entry $930.67 Now $952.40 +2.33% settles Dec 3
- Nov 3, 202613d ago Insider Cluster Neutral 2/10 Entry $930.67 Now $952.40 +2.33% settles Dec 3
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers